TIA
RANI icon

Traphagen Investment Advisors’s Rani Therapeutics RANI Stock Holding History

Traphagen Investment Advisors’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7K Hold
22,024
– – ﹤0.01% 220
2026
Q1 		$16.2K Buy
+22,024
New +$28.1K ﹤0.01% 206

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Traphagen Investment Advisors's RANI Position: Q2 2026 in Review

Traphagen Investment Advisors held its Rani Therapeutics (RANI) position steady in Q2 2026 at 22,024 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #220.

Traphagen Investment Advisors first reported a position in RANI in Q1 2026 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Traphagen Investment Advisors held 22,024 shares of Rani Therapeutics worth $16.7K as of Q2 2026.
  • Traphagen Investment Advisors left its Rani Therapeutics share count unchanged in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of Traphagen Investment Advisors's portfolio in Q2 2026, its #220 holding.
  • Traphagen Investment Advisors first reported a position in Rani Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Traphagen Investment Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.